Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia.

导出 LinkOut

翻译打印收藏纠错

作者： Anirban,Basu ^[1] ; Charmi,Patel ^[2] ; Alex Z,Fu ^[3] ; Brianne,Brown ^[3] ; Panagiotis,Mavros ^[4] ; Carmela,Benson ^[3]

作者单位： The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle. ^[1] Salutis Consulting LLC, Bellevue, WA. ^[2] Janssen Scientific Affairs, LLC, Titusville, NJ. ^[3] Georgetown University Medical Center, Washington, DC. ^[4] Kredhera, LLC, Hampton, NJ. ^[5]

主题词美国(United States);人类(Humans);成年人(Adult);精神分裂症(Schizophrenia);抗精神病药(Antipsychotic Agents);Medicaid(Medicaid);校准(Calibration);卫生保健费用(Health Care Costs);回顾性研究(Retrospective Studies)

DOI 10.18553/jmcp.2023.22191

PMID 36692909

发布时间 2023-08-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of managed care & specialty pharmacy

2023年29卷3期

293-302页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia.

Journal of managed care & specialty pharmacy

相似文献

Journal of managed care & specialty pharmacy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia.

Journal of managed care & specialty pharmacy

相似文献

Journal of managed care & specialty pharmacy

相关期刊

检索历史清除